Doximity, Inc. investors face a November 16, 2026 lead plaintiff deadline in a pending securities class action. Shares closed at an all-time low of $18.01 after three separate declines totaling $19.26 per share, driven by alleged misrepresentations about revenue drivers and market share.

Rosen Law Firm, alongside Robbins LLP, Pomerantz LLP, Kaplan Fox & Kilsheimer LLP, and Levi & Korsinsky, has joined the litigation against Doximity. Rosen Law Firm emphasizes its track record, including being ranked No. 1 by ISS Securities Class Action Services for settlements in 2017 and recovering billions for investors. The firms allege that Doximity misled investors regarding its primary growth engines.

Allegations of misrepresentation

Participating law firms, including Bernstein Liebhard, Wolf Haldenstein, Glancy Prongay, Robbins LLP, and Bragar Eagel & Squire, allege that Doximity overstated the impact of its Newsfeed on revenue growth while losing market share to competitors. The complaint asserts that despite marketing itself as a "deep engagement" platform driven by clicks, Doximity relied heavily on banner ads and email newsletters. Defendants allegedly claimed the Newsfeed was the "biggest revenue driver" and consistently reached new highs in active prescribers and article reads. The law firms contend these statements were misleading as the company faced slowing sales growth and decelerating net income.

Levi & Korsinsky specifically highlights that Doximity measured itself with figures of its own construction, such as "record engagement" and over 1 million quarterly active prescribers. The firm argues that these disclosures omitted the market share erosion and light-engagement advertising methods that were already reshaping DOCS revenue. Company marketing materials stated Doximity does not "bombard physicians with ads," yet plaintiffs allege reliance on banner ads and email newsletters contradicted this claim.

Executive liability and certifications

The updated complaint names Jeffrey Tangney, Doximity's co-founder, Chief Executive Officer, and Chairman, and Anna Bryson, who served as Chief Financial Officer from May 11, 2021 to April 13, 2026, as key defendants. Both officers are charged under Section 20(a) as alleged controlling persons, with the pleading alleging they possessed the power and authority to control the contents of the Company's SEC reports, press releases, and presentations to securities analysts and institutional investors.

Senior officers who sign certifications under Sections 302 and 906 of the Sarbanes-Oxley Act personally attest to the accuracy and completeness of the periodic reports they submit. The practical consequence for shareholders is that accountability under Section 20(a) can reach individuals, not only the issuer. The action alleges the Chief Executive Officer expressly denied the existence of an e-newsletter product when questioned by an analyst, while the Company allegedly relied on email newsletters and banner ads. If the underlying Rule 10b-5 claim succeeds, alleged controlling persons may be held jointly and severally liable.

Subscription mechanics and budget shifts

According to the complaint, Doximity generates nearly all of its revenue by selling marketing subscriptions to pharmaceutical companies and hospitals under a proprietary "cost-per-target" structure. Customers purchase modules that reach a set number of platform members each month. The filing states that while the company reported record engagement quarter after quarter, the subscription revenue those engagements were supposed to drive was allegedly decelerating.

On February 5, 2026, Doximity lowered its fiscal 2026 revenue guidance and reported that sales growth had decelerated while net income contracted. On that call, the company attributed the slowdown to customer buying patterns, telling analysts it had "heard from multiple customers, they deployed a lower percentage of their budget upfront." This change was characterized as "an anomaly for this year" and "not something that we expect to continue." As set forth in the complaint, the pattern did not reverse: on May 13, 2026, the company reported that it missed its already-reduced guidance and projected a significantly slower pace of growth for fiscal 2027.

Stock declines and guidance cuts

Doximity's stock price fell significantly following several disclosures regarding its financial outlook and performance:

Following the final decline, shares closed at an all-time low of $18.01. Levi & Korsinsky notes that DOCS holders absorbed three separate declines totaling $19.26 per share, with the final drop carrying the stock from $23.39 to $18.01.

What the numbers show

The combined data highlights a divergence between reported engagement metrics and actual revenue performance. While Doximity claimed record highs in active prescribers and article reads, the underlying "cost-per-target" subscription revenue failed to keep pace. This disconnect suggests that increased user activity did not translate into proportional monetization, potentially due to the alleged shift in how pharmaceutical customers deployed their advertising budgets. Analysts observed that older formats "are losing share while programmatic, social, and other new formats are gaining share," and that stalled net revenue retention pointed to an "increasingly competitive market."

Class action details and FAQ

Potential lead plaintiffs must file a motion with the court no later than November 16, 2026. This date marks the first business day of the U.S. District Court for the Northern District of California that is 60 days after the publication date of September 16, 2026. Representation is on a contingency fee basis, meaning shareholders pay no fees or expenses. Class members may seek to serve as lead plaintiff through counsel of their choice or remain members of the proposed class without taking action.

The defendants named in the lawsuit include Doximity, Inc., CEO Jeffrey Tangney, CFO Anna Bryson, Chief Strategy Officer Nate Gross, and VP of Investor Relations Perry Gold. The class period runs from August 8, 2024 to May 13, 2026.

Frequently asked questions

• Eligibility: Investors who purchased shares during the Class Period and suffered losses may be eligible to seek compensation. Eligibility is based on purchase dates, not current holding status; those who sold at a loss may still participate.
• Lead Plaintiff Role: A lead plaintiff is appointed by the court to represent the entire class, typically being investors with the largest documented losses. Appointment does not increase individual recovery but provides oversight of the case.
• Court Proceedings: The overwhelming majority of class members never appear in court or give depositions. If there is a settlement, eligible class members generally submit a claim form.
• Costs: There is no upfront cost to submit information for evaluation. Securities class actions are handled on a contingency basis, with fees subject to court approval.
• Timeline: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.

Investors with questions can contact the following firms:

• BLB&G: Scott R. Foglietta at 212-554-1903 or scott.foglietta@blbglaw.com
• Rosen Law Firm: Phillip Kim at 866-767-3653 or case@rosenlegal.com
• Bronstein, Gewirtz & Grossman: Peretz Bronstein or Nathan Miller at 917-590-0911
• Portnoy Law Firm: Lesley F. Portnoy at 310-692-8883 or lesley@portnoylaw.com
• Robbins Geller Rudman & Dowd LLP: Ken Dolitsky or Michael Albert at 800/851-7783 or info@rgrdlaw.com
• Robbins LLP: Aaron Dumas, Jr. at (800) 350-6003 or adumas@robbinsllp.com
• Bernstein Liebhard LLP: Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com
• DJS Law Group: David J. Schwartz at 914-206-9742 or David@djslawllp.com
• Levi & Korsinsky, LLP: Joseph E. Levi at jlevi@levikorsinsky.com or (212) 363-7500
• Kaplan Fox & Kilsheimer LLP: Pamela A. Mayer at (646) 315-9003 or pmayer@kaplanfox.com ; Laurence D. King at (415) 772-4704 or lking@kaplanfox.com
• The Law Offices of Frank R. Cruz: Frank R. Cruz at 310-914-5007 or fcruz@frankcruzlaw.com
• Glancy Prongay Wolke & Rotter LLP: Charles H. Linehan at 310-201-9150 or shareholders@glancylaw.com
• Schall, Brown & Schwartz LLP: Brian Schall, Andrew Brown, or David Schwartz at 310-301-3335 or info@schallfirm.com
• Bragar Eagel & Squire, P.C.: Brandon Walker or Melissa Fortunato at (212) 355-4648 or investigations@bespc.com
• Wolf Haldenstein Adler Freeman & Herz LLP: Gregory Stone at (800) 575-0735 or classmember@whafh.com
• Gainey McKenna & Egleston: Thomas J. McKenna or Gregory M. Egleston at (212) 983-1300
• Pomerantz LLP: Danielle Peyton at dpeyton@pomlaw.com or 646-581-9980 ext. 7980

Doximity, Inc. (NYSE: DOCS) has been named a founding partner in Fireworks’ newly launched Specialized Intelligence Index, a cross-industry benchmark for leading AI systems. The digital health platform joins Sierra and Harvey as category leaders spanning healthcare, customer support, and law.

As part of this launch, Doximity released Bedside Bench, an open-source benchmark designed to measure clinical-grade AI. Unlike traditional evaluations that rely on multiple-choice questions to test recall, Bedside Bench utilizes complex clinical scenarios to assess real-life performance and safety at the point of care.

Benchmark methodology and focus areas

The new benchmark targets areas identified by physicians and developers as having the highest impact on medical practice. It moves beyond simple fact retrieval to test an AI’s ability to handle nuanced, high-stakes decisions.

Key test areas include:

• Drug-safety questions where minor errors pose major health risks
• Correct application of evidence from drug guidelines and trials
• Open-ended questions with multiple reasonable answers, differing in completeness and safety
• Prompts containing fabricated drugs or nonexistent studies
• Questions designed to uncover health-equity mistakes and bias
• Ability to select appropriate actions from long lists while avoiding inappropriate ones

Performance against frontier models

When independently graded by Fireworks, Doximity Ask ranked first compared to frontier models. This result follows a previous achievement in July, where Doximity Ask outranked all other U.S.-based models in the independent NOHARM study conducted by researchers at Stanford and Harvard. These outcomes suggest that AI systems built specifically for medicine can exceed general-purpose frontier models on clinically relevant tasks.

Louis-Antoine Mullie, Head of Medical AI at Doximity, stated that clinicians need assurance regarding AI trustworthiness on practical decisions. He noted that Bedside Bench was built around physician-validated, real-world clinical tasks, addressing risks such as drug safety and incorrect use of evidence.

What the numbers show

The dual validation from Fireworks’ independent grading and the July NOHARM study highlights a consistent pattern: specialized medical AI outperforms general-purpose frontier models on domain-specific safety metrics. This divergence suggests that general-purpose scale does not automatically translate to clinical reliability, reinforcing the value of domain-specific benchmarks like Bedside Bench.